DCTH250417P22500
- 0.00
- 0.000.00%
Delcath Systems Newsroom
Delcath Systems Reveals Publication Of Comparative Analysis From Randomized Segment Of FOCUS Study In Metastatic Uveal Melanoma
Delcath Systems (NASDAQ:DCTH) Is In A Strong Position To Grow Its Business
Stryker, Boston Scientific Down as New Tariffs Impact Medtech Industry
Beta Bionics Announces Board Appointment of Gerard Michel
Beta Bionics Names Delcath Systems CEO Gerard Michel to Board
Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference
The 14% Return This Week Takes Delcath Systems' (NASDAQ:DCTH) Shareholders One-year Gains to 214%
Healthcare Up as Traders Rotate to Less Inflation-Sensitive Sectors -- Health Care Roundup
Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Express News | Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Stock Selloff Slashes Needed-market Cap for New Russell 2000 Additions: Stephens
BTIG Maintains Delcath Systems(DCTH.US) With Buy Rating, Maintains Target Price $22
Delcath Systems' Earnings Call Highlights Strong Growth and Strategic Expansion
Earnings Beat: Delcath Systems, Inc. (NASDAQ:DCTH) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
H.C. Wainwright Maintains Delcath Systems(DCTH.US) With Buy Rating, Raises Target Price to $24
Craig-Hallum Maintains Delcath Systems(DCTH.US) With Buy Rating, Announces Target Price $21
CCORF Maintains Delcath Systems(DCTH.US) With Buy Rating, Maintains Target Price $21
Positive Outlook for Delcath Systems: Promising Growth and Strategic Expansion Drive Buy Rating
Delcath Systems Price Target Raised to $24.00/Share From $22.00 by HC Wainwright & Co.
Delcath Systems Is Maintained at Buy by HC Wainwright & Co.